Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues in human Calpactin I Light Chain/S100A10 was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
S100 proteins are low-molecular-weight calcium-binding proteins of the EF-hand superfamily and appear to be involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation (1). Also, S100 proteins have been reported to localize to the plasma membrane in differentiated keratinocytes, suggesting a role in regulating calcium-dependent, membrane-associated events (3). The Calpactin I light chain (S100 calcium-binding protein A10; S100A10) is a member of the S100 family and it forms a heterotetrameric complex with another light chain, p11, and two heavy chains, annexin II and p36 (2). S100A10 is present in basal and spinous cells, in the cytoplasm, and is associated with the plasma membrane. S100A10, as well as a few other members of the S100 family, are suggested as transglutaminase substrates (3).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
